Most CEOs assume adoption is automatic.

Build a novel product, generate strong data, secure approval and adoption should follow.

But it rarely does.

That’s the Product Adoption Lie: the myth that better products naturally win.

In today’s healthcare economy, adoption is driven by market behavior, not product performance. Unless you deliberately rewire belief—teaching stakeholders a new way to see the problem and value the solution—even the best innovations stall.

The cost of ignoring this?

Burned budgets, missed milestones, and board confidence that evaporates before you can raise again.

In this briefing:

• 2 out of 3 launches will fail to hit projections and never catch up
• See how Proteus failed, even with a great product
• Learn a framework for assessing your risk
• These failures come with financial, operational, and reputational cost
• Testing (and investing in) market readiness gives you a roadmap to success
• Act: Get an easily shareable tool for your team and board

Every CEO believes they’ve done the hard part: validated the science, secured regulatory approval, and hired the right team. But the real test isn’t technical—it’s behavioral.

Markets don’t buy what’s better; they buy what they already believe in. And until belief shifts, behavior doesn’t.

That’s why two out of three healthcare launches fail to hit launch projections—and never catch up. Not because the innovation is weak, but the status quo is strong.

Most life sciences companies pour everything into proving the technology and launch with evidence. But if you haven’t done the work to reframe what’s broken and show why the market can’t live without your solution, you’re met with indifference.

Because producing data isn’t the same thing as producing demand.

This pattern repeats across all sectors of the industry. Strong products stall not because of execution gaps, but because belief was never built in the market. Before you can scale adoption, you have to see where belief breaks down.

Willing to take the chance? Best to understand the risk first.

Adoption isn’t automatic. It has to be designed.

Check out the story of Proteus, a seemingly unstoppable team…that failed spectacularly.

Proteus, once valued at more than $1.5 billion, spent nearly two decades perfecting a “smart pill,” an ingestible sensor paired with a wearable patch to track medication adherence. The technology worked. Regulators cleared it. Investors backed it.

But the market never believed it was necessary. Clinicians saw it as intrusive. Patients saw it as over-engineered. Payers saw it as unproven value.

Proteus proved the technology, but never made the market believe in the problem it solved. By 2020, the company had burned through more than $500 million and filed for bankruptcy.

Takeaway:

• Clinical proof shows what works in theory.
• Belief determines what works in practice.
• They validated the innovation. They never validated belief. 

The Product Adoption Lie Map helps CEOs visualize where belief breaks down between internal alignment and external market readiness.

Adoption doesn’t fail in the market. It fails in the mindset. 

See where your organization sits on the map and how great your launch exposure is.

Belief isn’t soft. It’s the most powerful force in business. Because once people believe, everything changes.

When belief isn’t built first, the cost is measurable:

• Financial: Go-to-market spend wasted chasing unready buyers.
• Operational: High-performing teams trapped in rework and reaction.
• Reputational: Boards lose confidence. Investors lose patience.

You can’t out-execute a market that hasn’t changed its mind.

Every dollar spent before belief is wired is launch insurance left unpaid.

The only way to avoid these costs is to validate readiness before you scale.

The cost of conviction is always lower than the cost of correction.

In the final stretch before launch, every team obsesses over what it can measure—pro formas, manufacturing runs, sales training decks, campaign calendars. But the metric that decides success isn’t on any of those spreadsheets.

You need to test belief before you scale—because readiness isn’t a marketing problem, it’s a market condition.

The smartest CEOs treat that moment as a commercial readiness check—an honest look at whether the market is truly prepared to follow before committing capital to execution.

That’s what the Product Adoption Lie Diagnostic delivers: a fast way to see where belief holds and where it fractures.

If your score shows you’re not Primed for Pull, you’re not ready to scale—yet.

The challenge? Most teams are confident that they are ready and that the market is ready. No one launches assuming they’ll fail. And yet extensive research and experience have shown that 66% of product launches fail. That’s why external calibration can serve as a safety net.

The diagnostic gives you the signal; the Pivotal Commercial Design Review (PCDR) turns that signal into a plan. The PCDR offers you the rare opportunity to safeguard your launch before capital, credibility, or time are lost. Because the cost of correction is a gamble you can’t afford to take.